Clinical Use of Lansoprazole and the Risk of Osteoporosis: A Nationwide Cohort Study

Ming-Hsuan Chung, Yong-Chen Chen, Wen-Tung Wu, Ming-Hsun Lin, Yun-Ju Yang, Dueng-Yuan Hueng, Tsung-Kun Lin, Yu-Ching Chou and Chien-An Sun ()
Additional contact information
Ming-Hsuan Chung: Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
Yong-Chen Chen: Data Science Center, College of Medicine, Fu-Jen Catholic University, New Taipei City 242, Taiwan
Wen-Tung Wu: Department of Pharmacy, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
Ming-Hsun Lin: Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
Yun-Ju Yang: Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
Dueng-Yuan Hueng: Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
Tsung-Kun Lin: School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan
Yu-Ching Chou: School of Public Health, National Defense Medical Center, Taipei 114, Taiwan
Chien-An Sun: Data Science Center, College of Medicine, Fu-Jen Catholic University, New Taipei City 242, Taiwan

IJERPH, 2022, vol. 19, issue 22, 1-9

Abstract: Background: Proton pump inhibitor (PPI) lansoprazole acts as a liver X receptor agonist, which plays a crucial role in the crosstalk of osteoblasts and osteoclasts in vitro and during bone turnover in vivo. However, epidemiological studies on the association between the use of lansoprazole and osteoporosis risk are limited. We aimed to determine the risk of developing osteoporosis in patients with lansoprazole use. Methods: A retrospective cohort study was conducted using the National Health Insurance Research Database of Taiwan dated from 2000 to 2013. The study includes 655 patients with lansoprazole use (the exposed cohort) and 2620 patients with other PPI use (the comparison cohort). The main outcome was the primary diagnosis of osteoporosis. The hazard ratios (HRs) and 95% confidence intervals (CIs) were used to assess the association between the use of lansoprazole and risk of osteoporosis. Results: Patients receiving lansoprazole treatment had a reduced risk of osteoporosis as compared with those undergoing other PPI therapy (adjusted HR, 0.56; 95% CI, 0.46–0.68). Moreover, this inverse association is evident in both sexes and in various age groups. Conclusions: This population-based cohort study demonstrated that lansoprazole use was associated with a reduced risk of osteoporosis. The clinical implications of the present study need further investigations.

Keywords: cohort study; lansoprazole; osteoporosis; proton pump inhibitors (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/22/15359/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/22/15359/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:22:p:15359-:d:978861

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().